Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.
Djamali
Arjang
A
Department of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Muth
Brenda L
BL
Torrealba
Jose
J
Bloom
Debra
D
Miller
Karen M
KM
Lorentzen
David
D
Sollinger
Hans W
HW
Pirsch
John D
JD
Mezrich
Joshua D
JD
D000208:Acute Disease; D000328:Adult; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003404:Creatinine / Q000652:urine; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery; D003928:Diabetic Nephropathies / Q000601:surgery; D004231:Diuresis / Q000187:drug effects; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007114:Immunization; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D016035:Pancreas Transplantation; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*
D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003404:Creatinine